As Chief Oncology Research & Development (ORD) Officer and Executive Vice President, Chris Boshoff leads Pfizer’s Oncology research and development organization from drug discovery to approval (including Oncology research) and through early and late phase clinical development.

Prior to Pfizer, Chris was the founding Director of the University College London (UCL) Cancer Institute, London, U.K.  He earned a PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. He is a Fellow of the Royal College of Physicians and an elected Fellow of the U.K. Academy of Medical Sciences. Chris was appointed an Adjunct Professor at Yale University School of Medicine in 2014, and as a clinician scientist has published more than 150 articles, many highly cited, on cancer biology, tumor virology, and experimental cancer medicine.

At Pfizer, Chris and his team have delivered numerous cancer medicines from Phase 1 to global approvals. This includes overseeing many U.S. Food and Drug Administration breakthrough therapy and European Medicines Agency Priority Medicines (PRIME) designations and delivering various Companion Diagnostics for Pfizer’s precision medicines—all with the goal of delivering breakthrough medicines for patients with cancer.